| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Amerita is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Schnepp Health Care Center is deeply committed to providing the highest quality rehabilitation services. Our facility offers a full-time physical therapist with full-time assistants and specially trained restorative nursing staff that continues to work
Integrative Emergency Services (IES) is a healthcare company that partners with Texas hospitals to provide the best patient encounter in emergency care. IES is transforming the way healthcare is practiced across the continuum of care and furthering the...
The Futures HealthCore is a Springfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.